Entering text into the input field will update the search result below

Diadexus inks distribution deal for PAC ELISA in Asia

Sep. 08, 2015 6:36 PM ETdiaDexus, Inc. (DDXS) StockDDXSBy: Douglas W. House, SA News Editor
  • Diadexus (OTCQB:DDXS) enters into an exclusive license and supply agreement with privately held Origene Technologies to develop and commercialize Diadexus' PLAC ELISA tests in certain Asian countries.
  • Under the terms of the agreement, Origene purchased $1M in DDXS stock at a premium to the recent 10-day average closing price. Diadexus will supply the raw materials and reagents necessary for Origene to assemble and market the kits in the Territory. Diadexus will be eligible to receive modest sales-based milestones and mid-single-digit royalties on net sales.
  • PLAC ELISA measures the concentration of circulating lipoprotein-associated phospholipase A2 in the blood. It is the only blood test cleared by the FDA to aid in assessing the risk for coronary heart disease and ischemic stroke associated with atherosclerosis.

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
DDXS--
diaDexus, Inc.